CHF Solutions (NSDQ:CHFS) announced today that it submitted a patent application for a new advance to its Aquadex SmartFlow system.
Eden Prairie, Minn.-based CHF Solutions develops Aquadex SmartFlow consoles for removing excess fluid from patients suffering from hypervolemia (fluid overload), which have recently been in demand due to capabilities in treating patients with COVID-19.
The new technological advance to the platform promotes venous blood flow in the arm of a patient, rather than a central vein, which is common with other systems, according to a news release.
Aquadex SmartFlow’s new innovation covered by the patent application is designed to improve efficiency in ultrafiltration, which CHF Solutions believes can lead to a shorter therapy time for the patient and fewer interventions for healthcare providers.
“At CHF Solutions, we are committed to developing innovative solutions that support medical professionals and their patients, and we invest in the protection of these innovations,” CHF Solutions CEO John Erb said in the release. “Our mission is to change the lives of patients suffering from fluid overload through science, collaboration, and innovation, and we continuously make moves to ensure we never lose sight of that goal.”
